About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 106 record(s)
Req # A-2019-001289
The following document: Pesticides, Soft Tissue Sarcoma, Lymphoma, and Multiple Myeloma. A Case Control Study in Three Regions of Canada. Report to Health and Welfare Canada on Project 6008-1223. The report in its entirety including all appendices, as we’ll as all communications pertaining to it in any manner.Organization: Health Canada
September 2022
Req # A-2019-001994
All records in connection with low glycemic foods and antioxidants in foods from 2017 to March 4, 2020.Organization: Health Canada
September 2022
September 2022
Req # A-2021-000819
The Signal Assessment: Typical (conventional) antipsychotics and All-cause Mortality (2009).Organization: Health Canada
September 2022
Req # A-2021-000937
Information on a product presently considered for access by Health Canada's Special Access Program (SAP). All products containing PSMA-11. Both 68Ga-labelled and 18F-labelled. The following information from requests made for the period September 1, 2019 to August 31, 2021. Hospital or clinic, Tradename or common name, Manufacturer, Indication for use of Drug, Quantity, Date of request.Organization: Health Canada
September 2022
Req # A-2021-001240
According to the Health Canada Generic Submissions Under Review List, an Abbreviated New Drug Submission (ANDS) for degarelix acetate was submitted on or after October 1, 2018. Documents containing information regarding the mock-ups of every label to be used in connection with the new drug including any package insert and any document that is provided on request and that sets out supplementary information on the use of the new drug and mock-ups of the new drug’s packages, as described in paragraph C.08.002(2)(j.1) of the Food and Drug Regulations.Organization: Health Canada
September 2022
Req # A-2021-001288
Disclosable Good Manufacturing Practices (GMP) inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the drug establishment licence GMP foreign evidence inspection of the Pfizer Healthcare India Pvt. Ltd. Plot No. 111 (Part), 116, 117, 118, 119 and 123 (Part), Jawaharlal Nehru Pharma City, Special Economic Zone, Parawada Mandal Visakhapatnam, Andhra Pradesh, India. 531019 conducted on or around 29 August, 2019. Reference Number 510512.Organization: Health Canada
September 2022
Req # A-2021-001768
The source data used in making policies related to mandatory vaccination against COVID-19 travel restrictions, namely in regard to the requirement for vaccination in order to travel within and out of Canada. All the data that the government relies on to decide the safety and efficacy of the COVID-19 vaccines, and formulate and implement their mandatory vaccination policies.Organization: Health Canada
September 2022
Req # A-2021-001959
Respecting ATIA requests A-2021-000734, A-2021-001017, and A-2021-001140, please provide the following records: Health Product and Food Branch (HPFB) recommendations, and summary documents thereof, completed Extension Justification Form(s), records referenced by any of the documents above.Organization: Health Canada
September 2022
Req # A-2022-000243
Health Canada issued a public advisory (Identification #RA-64122) on April 28, 2022 advising that Apotex Inc. is recalling five lots of Apo-Acyclovir tablets, in 200 mg and 800 mg strengths, due to the presence of N-nitrosodimethylamine (NDMA) above the acceptable level. Copies of any documentation or other information identifying the quantity of pills affected by the recall as well as the levels and/or concentrations of NDMA detected through testing of the recalled Apo-Acyclovir tablets. Any information in Health Canada’s possession concerning distribution of Apo-Acyclovir lots contaminated with NDMA by Apotex outside of Canada.Organization: Health Canada
September 2022